1. Home
  2. CIF vs EVAX Comparison

CIF vs EVAX Comparison

Compare CIF & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Intermediate High Income Fund

CIF

MFS Intermediate High Income Fund

HOLD

Current Price

$1.62

Market Cap

29.4M

Sector

Finance

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$4.01

Market Cap

31.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIF
EVAX
Founded
1988
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.4M
31.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CIF
EVAX
Price
$1.62
$4.01
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
64.6K
30.2K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
10.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$1.42
52 Week High
$1.82
$12.15

Technical Indicators

Market Signals
Indicator
CIF
EVAX
Relative Strength Index (RSI) 44.61 51.67
Support Level N/A $2.70
Resistance Level $1.73 $4.62
Average True Range (ATR) 0.02 0.33
MACD 0.00 -0.00
Stochastic Oscillator 18.18 54.80

Price Performance

Historical Comparison
CIF
EVAX

About CIF MFS Intermediate High Income Fund

Mfs Intermediate High Income Fund is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income, but it may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment-grade corporate bonds, government securities and other securities. The portfolio includes Midstream, Financial Institutions, Energy, Cable TV, and Utilities.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: